A Study of Atezolizumab in Advanced Solid Tumors

Exclusion Criteria

• •Malignancies other than disease under study within 5 years prior to Day 1 of Cycle 1 except those with a negligible risk of metastasis or death
• •Uncontrolled tumor-related pain
• •Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures \>/=1 time per month
• •History of asymptomatic or symptomatic central nervous system (CNS) metastasis
• •Leptomeningeal disease
• •Spinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated but without evidence that disease has been clinically stable for \>/=2 weeks prior to Day 1 of Cycle 1
• •Pregnant and lactating women
• •Significant cardiovascular disease within 3 months prior to Day 1 of Cycle 1
• •Severe infection within 4 weeks prior to Day 1 of Cycle 1
• •Oral or IV antibiotics within 2 weeks prior to Day 1 of Cycle 1
• •History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
• •Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or to any component of the atezolizumab formulation
• •History of autoimmune disease except treated/stable hypothyroidism, Type 1 diabetes mellitus, and protocol-specified dermatologic conditions
• •Active tuberculosis
• •Signs or symptoms of infection within 2 weeks prior to Day 1 of Cycle 1
• •Prior treatment with cluster of differentiation (CD) 137 agonists or immune checkpoint blockade therapies, or anti-programmed cell death-1 (PD-1) or anti-PD-L1 therapeutic antibodies
• •Treatment with systemic corticosteroids or other systemic immunosuppressive medications within 2 weeks prior to Day 1 of Cycle 1, or anticipated requirement for systemic immunosuppressive medications during the trial